Tirzepatide, the active ingredient in Zepbound and Mounjaro, also targets GIP (glucose-dependent insulinotropic polypeptide) alongside GLP-1
2013;1(1):44856 Turnberg LA, Bieberdorf FA, Morawski SG, Fordtran JS
The flexibility in timing for injectable semaglutide stems from its pharmacological properties
Recent study results shared at the Endocrine Society meeting ENDO 2026 indicate that semaglutide was linked to higher weight loss and a 15% decrease in broken bones when it was compared to other weight loss medications
In major European markets Germany, France, the U.K., Scandinavia biosimilar adoption for reference products like adalimumab, infliximab, and etanercept has been rapid and deep, with some reference products losing 80-90% of their market share within 12-18 months of biosimilar entry